Ticker Launch
Sign inTry it free

IPO · MORF

Morphic Holding, Inc.

Formerly Morphic Holding, LLC

Morphic Holding, Inc. (MORF) priced its initial public offering on Jun 27, 2019 at $15.00 per share, raising $90M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $443.9M. Jefferies was lead-left underwriter, joined by TD Cowen, BMO Capital Markets and Wells Fargo. Fenwick & West advised the company and Cooley advised the underwriters.

Morphic Holding, Inc. is a biopharmaceutical company using its integrin technology platform to discover and develop oral small-molecule integrin therapeutics. Integrins are targets of approved injectable drugs for autoimmune, cardiovascular, metabolic and fibrotic diseases and cancer, and the company is advancing a preclinical pipeline.

Status
IPO
Ticker
MORF
Exchange
Nasdaq Global Market
Priced
Jun 27, 2019
IPO price
$15.00
Raised
$90M
Market cap at IPO price
$443.9M
First filed
May 30, 2019
Underwriters
Jefferies, TD Cowen, BMO Capital Markets and Wells Fargo
Company counsel
Fenwick & West
Underwriters' counsel
Cooley
Sector
Biotech & pharma
Country / state
MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.

More on this listing for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other Biotech & pharma IPOs in 2019